Arcticzymes Technologies Asa · OSL:AZT
Arcticzymes Technologies Asa — Q3 2024 Earnings Presentation
25 slides from Arcticzymes Technologies Asa's earnings presentation, Nov 6, 2024
Slide 1: A Platform for Long-term Growth
A Platform for Long- November 6, 2024 CEO Michael Akoh term Growth CFO Børge Sørvoll Q3 2024
Slide 2: Overview
Overview Overview AANorwegian Norwegianbiotech biotech with with growth growth potential potential A provider of novel Customers are life World class products and Targeting segments with Worldclass Products enzymes for advanced considerable growth therapies and molecular Segment & Customers science
Slide 3: Agenda
Agenda 1 Highlights, commercial transformation and priorities 2 Sales update 3 Biomanufacturing update and future portfolio 4 Financials 5 Q&A
Slide 4: Highlights Q3 2024
Highlights Q3 2024 Publication on Achieved New VP of Sales ET-N1 in Nucleic revenue Paul Blackburn Acids Research 24.1 MNOK onboard in and acib Webinar (31.2 MNOK) September SAN OEM EBITDA agreement and SAN White paper Performance CDMO integration released -2.3 MNOK progressing confirming portfolio
Slide 5: Commercial Transformation
Commercial Transformation Increased investment in commercial transformation to drive growth in coming years Commercial Transformation The Board and management are aligned in accelerating ArcticZymes' commercial transformation, building on past successes to capture new market opportunities Solution P
Slide 6: Strategic priorities
Strategic priorities Building a platform for long term growth – the journey has started Short Term Long Term Build Advanced therapies biomanufacturing pipeline to 1 Continue journey to become customer centric 1 broaden and diversify portfolio Commercialization – strengthen commercial arm significant
Slide 7: Customer centric organisation
Customer centric organisation The commercial transformation journey What Why When Ensure a market and customer driven 1 Balance between Internal and customer focused resources organisation Q1 2024- Align development portfolio with market 2 Strategic pipeline review and future portfolio road map need
Slide 8: Investment in commercial transformation
Investment in commercial transformation New website, webinars, whitepapers, talks, publications and collaborations
Slide 9: New VP of Sales – Paul Blackburn
New VP of Sales – Paul Blackburn Driver of commercial transformation Joined: September 2024 Qualifications: Ph.D. in Vaccine Development (University of Glasgow); Degree in Medical Microbiology (University of Edinburgh) Experience: Over 20 years in life sciences with a strong technical and commercial
Slide 10: Sales Update Q3 2024
Sales Update Q3 2024
Slide 11: Total Sales
Total Sales Molecular tools down and upward trend for Biomanufacturing Combined sales ✓ Quarterly sales of 23.3 MNOK (31.2 MNOK) ✓ Sales impacted by performance in Molecular tools segment ✓ 58% of sales coming from the USA, 41% EMEA and 1% APAC ✓ Q3 2023: 43%, 56% and 1%, respectively 11
Slide 12: Sales per area: Molecular Tools
Sales per area Commercial Molecular Tools ✓ Weak quarter driven by absence of major order from key account ✓ Accounts for 44% of total Q3 sales ✓ Expect organic growth opportunities, especially with its Endonuclease and Polymerase product offerings during 2025 12
Slide 13: Sales per area: Biomanufacturing
Sales per area Commercial Biomanufacturing ✓ Quarterly sales 12.7 MNOK ✓ Positive trend during last 3 consecutive quarters in a challenging environment ✓ Accounts for 56% of total Q3 sales ✓ SAN HQ GMP continues to be picking up in sales ✓ High interest in segment also from competitors ✓ Increase in
Slide 14: Biomanufacturing Update
Biomanufacturing Update
Slide 15: SAN market overview
SAN market oveview Intensified competition but SAN portfolio remains competitive Strong Interest: Significant interest in the segment, with competitors closely following ArcticZymes’ advancements Published Insights: Released a whitepaper on Select Science titled "Efficient Chromatin Removal in Viral
Slide 16: SAN OEM update
SAN OEM update Proceeding according to plan Active Partner Engagement: Ongoing discussions with multiple potential partners New Product Launch: OEM agreement discussions for new SAN product, launching in December 2024 Supply and Rebranding: ArcticZymes to provide bulk material for repackaging and re
Slide 17: CDMO opportunities
CDMO opportunities Becoming the standard nuclease on a CDMO platform Trend in the CGT space - a return to the CDMO model Trough a partnership with CDMOs we will expand our reach significantly into several projects at once M-SAN and SAN has been tested in an initial study with good data outcome at CD
Slide 18: The future portfolio - Diversification
The future portfolio - 18 Diversification
Slide 19: RNA based therapeutics update
RNA based therapeutics update AZT’s first innovation - «RNA restriction enzyme ET-N1» Enzymes are key in development, analytics and manufacturing process of mRNA AZT is now exploring new innovations in the field of RNA therapeutics through RCN funded collaboration project. First major innovation is
Slide 20: Expenses & Profitability
Expenses & Profitability
Slide 21: Profitability and expenses
Profitability and expenses Expense development continue according to plan Margin 20 % 24 % 23 % 7% 8% 10 % -10 % 21
Slide 22: …but Q3 also impacted by other items
…but Q3 also impacted by other items One-offs and extraordinary • Q3 2024 impacted negatively by MNOK 1.2 in ERP implementation. Expected to be finalised in 2H 2024. 22
Slide 23: Cash flow and short-term investments
Cash flow and short-term investments +0.9 MNOK in changes for Q3* 23 *includes changes in STI of +1.1 MNOK
Slide 24: Outlook
Outlook • SAN OEM Opportunity: Term sheet expected to finalize by early Q1, contingent on successful negotiation, with expected contributions to SAN revenue growth in Q2/Q3 2025. • CDMO platform progress: Successful evaluation of SAN by CDMO partner presented at ESGCT, positioning it for platform im
Slide 25: Thank you Q&A
Thank you Q&A arcticzymes.com
ArcticZymes Technologies — Q3 2024 Earnings Presentation on 6ix